Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fupu Ganmao Granules (芙朴感冒颗粒) is a Traditional Chinese Medicine (TCM) formulation developed by Zhejiang Tianyitang Pharmaceutical for the treatment of influenza, specifically targeting the 'wind-heat attacking the exterior' syndrome. As a botanical-based therapy, it is composed of multiple herbal extracts intended to alleviate symptoms such as fever, sore throat, and cough associated with viral respiratory infections. The drug is currently being evaluated in a multicenter Phase II clinical trial (CTR20254989) in China to explore its efficacy, safety, and optimal dosing for influenza patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fupu Ganmao Granules.